Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Minghui Pharmaceutical (Hangzhou)
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07130383 | https://clinicaltrials.gov/study/NCT07192120
Assets
Linked programs
- MHB036C for Injection: Operational Burden Signal (2/5)
- MHB048C for Injection: Operational Burden Signal (2/5)